APRI评分对慢性乙型肝炎肝纤维化程度的诊断及预测价值

吴方雄; 高保华; 牛春燕; 孙娟; 汪雯; 朱琳; 罗建梅; 郑建云

doi:10.3969/j.issn.1001-5256.2017.08.014

APRI评分对慢性乙型肝炎肝纤维化程度的诊断及预测价值

DOI: 10.3969/j.issn.1001-5256.2017.08.014

1. 西安医学院第一附属医院消化内科
2. 西安医学院第一附属医院超声科
3. 西安医学院第一附属医院病理科

基金项目:

陕西省教育厅科学研究项目计划(12JK0704)；陕西省普通高等学校优势学科建设项目(陕教位[2014]3号文件)；

详细信息

中图分类号: R512.62;R575.2
计量
- 文章访问数: 3221
- HTML全文浏览量: 53
- PDF下载量: 450
- 被引次数: 24
出版历程
- 收稿日期: 2017-02-06
- 出版日期: 2017-08-20

Value of aspartate aminotransferase-to-platelet ratio index in diagnosis and prediction of liver fibrosis degree in patients with chronic hepatitis B

Department of Gastroenterology, The First Affiliated Hospital of Xi'an Medical University

Research funding:

摘要

摘要: 目的评估APRI（AST与PLT比值指数）对慢性乙型肝炎肝纤维化的诊断及预测价值。方法收集2014年1月-2016年12月在西安医学院第一附属医院首次诊断且未经治疗的慢性乙型肝炎患者69例,其中HBeAg阳性37例,阴性32例,行肝穿刺活组织检查,病理组织学方法评价肝组织炎症及纤维化程度。计算APRI,绘制受试者工作特征曲线,并分析与肝组织纤维化程度的关系。正态分布的计量资料两组间比较采用独立样本t检验;非正态分布的计量资料两组间比较采用Mann-Whitney U检验,多组间比较采用Kruskal-Wallis H检验。计数资料两组间比较采用χ2检验。结果 HBeAg阴性组患者的APRI[0.890（0.3703.000）]高于HBeAg阳性组[0.520（0.3550.652）],差异有统计学意义（Z=-2.024,P=0.025）;不同肝纤维化程度的APRI比较,差异有统计学意义（χ2=10.004,P=0.040）。APRI预测中重度肝纤维化（≥F2）的cut-off值为1.06,受试者工作...
- 肝炎,乙型,慢性 /
- 肝硬化 /
- AST/PLT比率指数 /
- 诊断
Abstract: Objective To investigate the value of aspartate aminotransferase-to-platelet ratio index ( APRI) in the diagnosis and prediction of liver fibrosis degree in patients with chronic hepatitis B ( CHB) . Methods A total of 69 treatment-na6 ve CHB patients who were diagnosed in The First Affiliated Hospital of Xi'an Medical University from January 2014 to December 2016 were enrolled, and among these patients, 37 had positive HBeAg and 32 had negative HBeAg. Liver biopsy was performed, and a histopathological method was used to evaluate liver inflammation and fibrosis degree. APRI was calculated, the receiver operating characteristic ( ROC) curve was plotted, and the correlation between APRI and liver fibrosis degree was analyzed. The independent samples t-test was used for normally distributed continuous data between two groups, the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups, and the Kruskal-Wallis H test was used for comparison between multiple groups. The chi-square test was used for comparison of categorical data between groups. Results The HBeAg-negative group had a significantly higher APRI than the HBeAg-positive group[0. 890 ( 0. 370-3. 000) vs 0. 520 ( 0. 355-0. 652) , Z =-2. 024, P = 0. 025], and there was a significant difference in APRI between patients with different liver fibrosis degrees ( χ2= 10. 004, P = 0. 040) . The cut-off value of APRI for predicting severe liver fibrosis ( ≥F2) was 1. 06, and the area under the ROC curve was 0. 673 ( 95% CI: 0. 426-0. 920) . Conclusion APRI has a good value in the diagnosis and prediction of liver fibrosis degree and stage in patients with CHB.
- hepatitis B, chronic /
- liver cirrhosis /
- APRI /
- diagnosis

HTML全文

参考文献(16)

[1]WHO Guidelines Approved by the Guidelines Review Committee.Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[J].Geneva:World Health Organization, 2015.

[2]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:the major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.

[3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[4]BEDOSSA P, POYNARD T.An algorithm for the grading of activity in chronic hepatitis C.The METAVIR Cooperative Study Group[J].Hepatology, 1996, 24 (2) :289-293.

[5] HAN XY, CHEN XJ, YAN ZQ, et al.Correlation among HBs Ag and HBV DNA levels with liver fibrosis in patients with hepatitis B[J].Int J Virol, 2016, 23 (1) :50-56. (in Chinese) 韩晓颖, 陈秀记, 闫泽强, 等.血清HBs Ag与HBV DNA水平与乙肝患者肝纤维化程度的相关性分析[J].国际病毒学杂志, 2016, 23 (1) :50-56.

[6]PARIKH P, RYAN JD, TSOCHATZIS EA.Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection[J].Ann Transl Med, 2017, 5 (3) :40-53.

[7]MARCELLIN P, GANE E, BUTI M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study[J].Lancet, 2013, 381 (9865) :468-475.

[8]MERLI M, GALLI L, CASTAGNA A, et al.Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients[J].New Microbiol, 2016, 39 (2) :110-113.

[9]PAGGI S, COLLI A, FRAQUELLI M, et al.A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C:a comparison using histology with internal-external validation[J].J Hepatol, 2008, 49 (4) :564-571.

[10]PETERSEN JR, STEVENSON HL, KASTURI KS, et al.Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C[J].J Clin Gastroenterol, 2014, 48 (4) :370-376.

[11]CHENG J, ZHAO P, LIU J, et al.Preoperative aspartate aminotransferase-to-platelet ratio index (APRI) is a predictor on postoperative outcomes of hepatocellular carcinoma[J].Medicine (Baltimore) , 2016, 95 (48) :e5486.

[12]XIAO G, ZHU F, WANG M, et al.Diagnostic accuracy of APRI and FIB-4 for predicting hepatitis B virus-related liver fibrosis accompanied with hepatocellular carcinoma[J].Dig Liver Dis, 2016, 48 (10) :1220-1226.

[13]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[14]ZHANG Z, WANG G, KANG K, et al.The diagnostic accuracy and clinical utility of three noninvasive models for predicting liver fibrosis in patients with HBV infection[J].PLo S One, 2016, 11 (4) :e0152757.

[15]ZHANG X, WANG Y, MA J, et al.Value of five noninvasive diagnostic techniques and their combinations in diagnosis of liver fibrosis in patients with chronic hepatitis B[J].J Clin Hepatol, 2016, 32 (10) :1888-1893. (in Chinese) 张旭, 王煜, 马娟, 等.5种无创诊断技术单独及联合应用对慢性乙型肝炎肝纤维化的诊断价值比较[J].临床肝胆病杂志, 2016, 32 (10) :1888-1893.

[16]HOUOT M, NGO Y, MUNTEANU M, et al.Systematic review with meta-analysis:direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B[J].Aliment Pharmacol Ther, 2016, 43 (1) :16-29.

施引文献

期刊类型引用(10)

1.	刘听潮，张示杰，杨婧，彭心宇，马儒林，郭恒，张向辉，何佳，郭淑霞. 新疆维吾尔族农村居民肝纤维化评分与心血管疾病发病关系前瞻性队列研究. 中国公共卫生. 2025(02): 154-160 . 百度学术
2.	卢晶，朴红心，金雪梅，崔京淑，金仁顺. 慢性乙型肝炎肝纤维化抗病毒治疗后生活质量与AST/PLT比率、肝硬度值、病理组织学的相关性分析. 临床肝胆病杂志. 2021(04): 813-816 . 本站查看
3.	刘红虹，福军亮，洪智贤，靳雪原，陈曦，王文苓，王冶，赵艳玲. 肝纤维化血清学无创检测研究进展. 传染病信息. 2021(04): 347-352 . 百度学术
4.	魏鑫，徐懂，龙细雨，伍喜良，郭丽颖，贾建伟. 基于血清Fe和CA199预测模型对慢性乙型肝炎患者肝纤维化分期的临床研究. 中西医结合肝病杂志. 2021(10): 869-873 . 百度学术
5.	郑少秋，王启之. 无创肝纤维化诊断研究现状与前景. 临床肝胆病杂志. 2019(01): 197-200 . 本站查看
6.	徐莉力，王佳冰，杨华睿，童明辉. 肝、脾二维实时剪切波弹性成像技术及血清纤维化模型对CHB肝脏纤维化程度的评估原理与应用. 武警医学. 2019(02): 169-173 . 百度学术
7.	吴方雄，闫蓉，高保华，田秋梅，徐静远，鲁晓岚. RPR FIB-4 APRI及AAR对107例慢性乙型肝炎肝纤维化的诊断准确性比较. 中国实用内科杂志. 2019(03): 249-253 . 百度学术
8.	张丽杰，张古城，申弘，胡萌，张均倡. 中西医结合治疗对乙肝肝硬化代偿期患者逆转情况的队列研究. 湖南师范大学学报(医学版). 2019(01): 34-38 . 百度学术
9.	许峰铭，盛庆寿. 血清标志物与瞬时弹性成像技术评估肝纤维化的研究进展. 临床肝胆病杂志. 2018(03): 618-622 . 本站查看
10.	富慧文. 血府逐瘀汤治疗慢性乙型肝炎肝纤维化的效果研究. 名医. 2018(08): 9+14 . 百度学术